Genmab revenue and financials

GMAB · NASDAQ · USD

Secondary listing. The primary listing is Genmab · Nasdaq Copenhagen (DKK)

$37.80−1.77%−$0.68

Close · October 6, 2026

In the fiscal year ended December 2025, Genmab reported revenue of kr 3.72B (+19.19% year over year). Net income was kr 963M, a net margin of 25.9%.

Annual revenue · 2025: kr 3.72B
  1. kr 2.37B2017
  2. kr 3.03B2018
  3. kr 5.37B2019
  4. kr 2.39B2023
  5. kr 3.12B2024
  6. kr 3.72B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+19.19%
2025 vs 2024
Net income growth
−87.72%
2025 vs 2024
Net margin
25.9%
2024: 251.3%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue1,1558961,0581,0229257151,027829779603706668
Cost of revenue84.065.081.058.057.042.053.040.828.027.018.711.2
Gross profit1,071831977964868673974788751576687657
Selling, general and administrative205166208148144126196129129125139122
Research and development459440526357364359431341361335289296
Operating income407225243459360188347317261116260239
EBIT407225243459360188347317261116260239
EBITDA423244253471376204353330271126265248
Interest expense11011244.03.09.05.08.82.73.04.03.11.3
Pre-tax income29574.055.0482423244554257307249149379
Income tax-8.021.024.081.087.049.0-24.067.810457.045.180.3
Net income30353.031.0401336195578189203192104298
Net income to common shareholders30353.031.0401336195578189203192104298
Basic EPS4.940.840.506.515.443.069.102.983.152.961.604.57
Diluted EPS4.910.830.506.465.423.059.002.963.132.941.584.53
Average shares (basic)61.363.161.661.661.863.763.563.564.464.965.365.3
Average shares (diluted)61.763.963.162.162.063.964.263.964.965.366.165.9